Insider buying last 90 days
No open-market insider purchases were filed for XERS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every XERS insider filing, plotted on the chart in Gekko.Open XERS in Gekko
NASDAQ: XERS
Xeris Biopharma (XERS) Stock Analysis & Forecast
Oct 12 close
$10.46−0.02 (−0.2%)
Gekko Brief
AI summaryOct 12 closeXeris Biopharma moves this week on continued reaction to its Q2 2026 results and a subsequent analyst action. Barclays raised its price target on XERS to USD 14.00 from USD 12.00 while maintaining an Overweight rating, citing net product revenue growth of 34% year-over-year and Recorlev's 81% surge. This follows the company's record Q2 2026 total revenue of $92 million, with Recorlev leading at $57 million, Gvoke at $23 million, and Keveyis at $12 million.
XERS closes at $10.46, above both its 50-day average of $8.69 and 200-day average of $7.29, with the shorter average above the longer one. The stock's one-month return stands at 40.4% and its six-month return at 75.2%. The GekkoIndex reads 48.3, placing it in the Neutral zone, while the price sits 1.3% above Gekko Fair Value of $10.33.
The next earnings date falls on 5 November 2026, before the open, which is 24 days away and inside a typical 20-trading-day holding window. The prior quarter's EPS of -0.18 missed the estimate of 0.01, with an average absolute reaction of 10.5% historically. No insider, Congress, or unusual options activity appears in the current window. Seasonality from this point in the calendar shows a 5.7% average return over the next 20 trading days across 5 years, with gains in 3 of them. Analyst consensus across 6 firms shows 5 buy ratings and 1 hold, with a consensus target of $12.86.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Xeris Biopharma price vs fair value
Close $10.46200-day averageGekko Fair Value $10.33
Xeris Biopharma quick facts
- Market cap
- $1.81B
- P/E ratio
- —
- Forward P/E
- 36.9
- EPS, TTM
- −$0.10
- Revenue, TTM
- $335.4M
- Profit margin
- -5.1%
- Dividend yield
- —
- Beta
- 0.84
- Volume
- 1.33M avg 3.19M
- 1-year return
- +27.7%
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±11%
- 50-day average
- $8.69
- 200-day average
- $7.29
- Next earnings
- Nov 5 before open
- Shares outstanding
- 182.3M
Xeris Biopharma swing-trade checklist
Xeris Biopharma scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $10.46 is above the 50-day ($8.69) and 200-day ($7.29) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
48.3, Neutral
Reading 48.3 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
1.3% above
Price is within 5% of Gekko Fair Value (1.3% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.7% on average
From this point in the calendar, the next 20 trading days averaged +5.7% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Xeris Biopharma stock chart and price history
Xeris Biopharma closed at $10.46 on Oct 12, 2026, +27.7% over the past year, inside a 52-week range of $5.25 to $11.33.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +40.4%
- 3 months
- +26.3%
- 6 months
- +75.2%
- 1 year
- +27.7%
The full XERS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open XERS in Gekko
Follow Xeris Biopharma through every session
Put XERS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track XERS in GekkoFree for 7 days. No credit card required.
About Xeris Biopharma
Xeris Biopharma develops and sells medicines for patients dealing with hormonal, neurological, and digestive conditions. Among its products are Gvoke, a liquid glucagon formulation prepared for immediate use in cases of severe low blood sugar, Keveyis, a treatment for several forms of primary periodic paralysis linked to potassium imbalances, and Recorlev, a drug that limits cortisol production and is approved for adults with Cushing's syndrome caused by excess internal cortisol.
Alongside these marketed therapies, Xeris Biopharma continues to work on new treatment possibilities, both by expanding the uses of its existing drugs and by developing additional products built on its own XeriSol and XeriJect formulation platforms.
The company was established in 2005 and runs its operations from Chicago, Illinois. Its shares trade on the NASDAQ under the ticker XERS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- xerispharma.com
Xeris Biopharma GekkoIndex: the smart money zone
Xeris Biopharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.3, in the Neutral zone, down 0.2 points over five sessions.
48.3Neutral
Down 0.2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | +0.3% | +9.6% | ||
| Accumulation | 159 | +1.5% | +5.4% | ||
| Neutral (current zone) | 413 | +1.4% | +6.2% | ||
| Distribution | 66 | +1.2% | −4.4% | ||
| Selling | 6 | Too few readings yet | |||
Average XERS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the XERS price, zone by zone.Track XERS in Gekko
Is Xeris Biopharma stock overvalued? Gekko Fair Value
Xeris Biopharma trades 1.3% above Gekko Fair Value of $10.33, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Xeris Biopharma shares are worth, recalculated every trading day.
$10.33
Gekko Fair Value, Oct 10, 2026
1.3% above fair value · About fair value
At the end of Aug 2026 the price was 19.7% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open XERS in Gekko
Xeris Biopharma insider and Congress trading
No open-market insider purchases were filed for Xeris Biopharma, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in XERS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for XERS, plotted on the chart in Gekko.Open XERS in Gekko
Buybacks
Xeris Biopharma has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $191K
- As a share of market cap
- 0.01%
- Trailing four quarters
- $19.23M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold XERS.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Xeris Biopharma earnings: next date and track record
Xeris Biopharma reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- $0.03
- Revenue estimate
- $101.7M
5 of 8reports beat the EPS estimate
±10.5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Xeris Biopharma reported record Q2 2026 total revenue of $92 million (net product revenue $91 million), up 34% year-over-year. Recorlev led growth at $57 million (+81% YoY), Gvoke rebounded to $23 million (+10% sequentially), and Keveyis delivered $12 million. Post-quarter, the company retired convertible notes, eliminating ~$3 million in annual interest expense and simplifying its capital structure. IP portfolio strengthening was also highlighted as a strategic priority.
- Guidance
- Management raised the bottom end of full year 2026 total revenue guidance to $385-$390 million, reflecting strong H1 performance and confidence in continued portfolio growth. The expanded Recorlev sales force deployed in January is expected to accelerate growth in H2.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.18 est $0.01 | $91.00M est $90.13M | −2.2% |
| May 7, 2026 | $0.01 est $0.00 | $82.45M est $79.83M | +2.5% |
| Mar 2, 2026 | $0.06 est $0.03 | $85.81M est $82.20M | −2.9% |
| Nov 6, 2025 | $0.00 est $0.01 | $74.38M est $86.00M | −24.7% |
| Aug 7, 2025 | −$0.01 est −$0.03 | $71.54M est $72.25M | +24.6% |
| May 8, 2025 | −$0.06 est −$0.07 | $60.12M est $57.61M | +11.8% |
| Mar 6, 2025 | −$0.03 est −$0.08 | $60.10M est $54.90M | +12.5% |
| Nov 8, 2024 | −$0.11 est −$0.09 | $54.27M est $51.43M | −2.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Xeris Biopharma stock forecast and analyst price targets
Analysts’ average 12-month price target for Xeris Biopharma is $12.86, +22.9% from the last close, from 6 firms rating the stock in the last 90 days.
$12.86consensus 12-month target, +22.9% from the last close
Now $10.46Avg $12.86
Low $8High $18
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 6 | Barclays | $14 | +33.8% |
| Sep 29 | Craig-Hallum | $12 | +14.7% |
| Sep 21 | H.C. Wainwright | $10 | −4.4% |
| Sep 10 | Oppenheimer | $18 | +72.1% |
| Sep 10 | Craig-Hallum | $12 | +14.7% |
+6.2%average 20-day move after past Neutral readings
+5.7%average move over the next 20 trading days in the last 5 years
±5.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Xeris Biopharma seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Xeris Biopharma averaged +5.7% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.1% | 3 of 5 |
| Next 10 trading days | +6.2% | 4 of 5 |
| Next 15 trading days | +10.4% | 4 of 5 |
| Next 20 trading days | +5.7% | 3 of 5 |
| Next 30 trading days | −1.4% | 3 of 5 |
For scale, XERS’s typical 20-trading-day move in either direction is about 11%.
Xeris Biopharma market cap and key statistics
Xeris Biopharma’s market cap is $1.81B and revenue of $335.4M over the last twelve months.
Valuation
- Market cap
- $1.81B
- Forward P/E
- 36.9
- EPS, TTM
- −$0.10
- Gekko Fair Value
- $10.33
Trading
- Volume
- 1.33M
- Avg volume, 20 days
- 3.19M
- 52-week high
- $11.33
- 52-week low
- $5.25
- Shares outstanding
- 182.3M
Financials
- Revenue, TTM
- $335.4M
- Profit margin
- -5.1%
- Return on equity
- -617%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.84
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±11%
Xeris Biopharma stock news this week
2 headlines about Xeris Biopharma from the past week, newest first, each linking to the publisher.
- Barclays raised Xeris Biopharma stock target to USD 14.00AD HOC NEWS, Oct 8
- Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings CallBenzinga, Oct 6
Xeris Biopharma peers
Xeris Biopharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Xeris Biopharma stock FAQ
What is Xeris Biopharma’s market cap?
Xeris Biopharma’s market cap is $1.81B at the Oct 12, 2026 close of $10.46, with 182.3M shares outstanding.
What is the Xeris Biopharma stock forecast?
The consensus analyst 12-month price target for Xeris Biopharma is $12.86, +22.9% from the last close. Of the 6 firms that rated the stock in the last 90 days, 5 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Xeris Biopharma stock overvalued or undervalued?
On Gekko’s estimate Xeris Biopharma is about fair value: the Oct 12, 2026 close of $10.46 is 1.3% above Gekko Fair Value of $10.33. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Xeris Biopharma report earnings next?
Xeris Biopharma is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of $0.03 per share on revenue of $101.7M. Xeris Biopharma beat the earnings estimate in 5 of its last 8 reports, moving 10.5% on average across the report.
What is Xeris Biopharma’s 52-week high and low?
Xeris Biopharma’s 52-week high is $11.33 and its 52-week low is $5.25; it closed at $10.46 on Oct 12, 2026, +27.7% over the past year.
Is Xeris Biopharma stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and seasonality), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Xeris Biopharma the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.